Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 7,852 matching trials from the live ClinicalTrials.gov search.
Filters: Minneapolis, Minnesota Clear all
Enrolling by invitation Not applicable Interventional

Acolyte CTO-PCI Study: Imaging and Catheter System to Treat Patients With Coronary Chronic Total Occlusion, Who Have Persistent Symptoms Following Medical Therapy and Are Undergoing Percutaneous Coronary Interventional Procedures

NCT06795763
View directory record Official record
Conditions
Coronary Chronic Total Occlusions, Ischemic Heart Disease, Ischemic Heart Disease (IHD), Ischemic Heart Disease Chronic
Interventions
CTO-PCI Procedure with Acolyte Catheter System
Device
Lead sponsor
Elumn8 Medical
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Roslyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406
View directory record Official record
Conditions
Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Encorafenib, Cetuximab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Patient Observation
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
202
States / cities
Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 159 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer

NCT00707304
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Talactoferrin, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Oct 31, 2026, 2:31 AM EDT
Terminated Phase 4 Interventional

Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation

NCT00177138
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Tacrolimus, Alemtuzumab
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 31, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata

NCT06747611
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
Vancomycin, Neomycin and MTT capsules, Placebo capsules
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

NCT02112071
View directory record Official record
Conditions
Focus Type 2 Diabetes Related Chronic Kidney Disease
Interventions
Exercise
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2015 · Synced Oct 31, 2026, 2:31 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)

NCT01302587
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
25
States / cities
Glendale, Arizona • Mission Viejo, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

NCT00528606
View directory record Official record
Conditions
Dupuytren's Contracture
Interventions
collagenase clostridium histolyticum, Placebo
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Effect of a Decision Aid on Shared Decision Making for Prostate Cancer Screening

NCT01484665
View directory record Official record
Conditions
Prostate Cancer
Interventions
PROCASE Decision-Aid
Other
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 4 Interventional Results available

Ketamine Versus Etomidate for Rapid Sequence Intubation

NCT01823328
View directory record Official record
Conditions
Airway Control, Anesthesia, Intubation, Complication
Interventions
Ketamine, Etomidate
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 31, 2026, 2:31 AM EDT
Completed No phase listed Observational

The GRADE Capillary Blood Collection Pilot Study

NCT02388100
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Capillary HbA1c collection
Procedure
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Denver, Colorado • Honolulu, Hawaii + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

NCT00762034
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pemetrexed, Paclitaxel, Carboplatin, Bevacizumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
67
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Alhambra, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Vyvanse in Children Aged 6 to 12 Years

NCT05416125
View directory record Official record
Conditions
Obesity, Childhood
Interventions
Lisdexamfetamine Dimesylate, Lifestyle therapy
Drug · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Pivotal IDE Study of the BRYAN(R) Cervical Disc Prosthesis in the Treatment of DDD Versus ACDF

NCT00437190
View directory record Official record
Conditions
Radiculopathy, Myelopathy, Cervical Degenerative Disc Disease
Interventions
ATLANTIS™ Cervical Plate System and allograft, BRYAN Cervical Disc Prosthesis
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
21 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Campbell, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Not applicable Interventional Results available

Diabetes Homeless Medication Support Single Arm Treatment Development Trial

NCT04678284
View directory record Official record
Conditions
Type 2 Diabetes, Homeless Persons
Interventions
Diabetes Homeless Medication Support (D-Homes)
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, Seralutinib, Generic Dry Powder Inhaler
Drug · Device
Lead sponsor
GB002, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Exenatide in Extreme Pediatric Obesity

NCT01237197
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 31, 2026, 2:31 AM EDT
Recruiting Phase 1Phase 2 Interventional

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Yazeed Sawalha
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Recruiting Not applicable Interventional

Combining a Smartphone App With Medications to Manage Heavy Drinking

NCT06303778
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Stand Down mobile app, Standard Care
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Communication in Older Cancer Patients and Their Caregivers

NCT02107443
View directory record Official record
Conditions
Adult Solid Neoplasm, Lymphoma
Interventions
Geriatric Assessment Summary, Geriatric Assessment Targeted Recommendations, Geriatric Assessment (GA)
Behavioral
Lead sponsor
Supriya Mohile
Other
Eligibility
70 Years and older
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
19
States / cities
Duarte, California • Newark, Delaware • Honolulu, Hawaii + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 31, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044408
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
13
States / cities
Long Beach, California • Norwalk, Connecticut • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 31, 2026, 2:31 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity

NCT01327976
View directory record Official record
Conditions
Obesity
Interventions
vBloc (Active Device), Sham (Non-active Device)
Device
Lead sponsor
ReShape Lifesciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
8
States / cities
Scottsdale, Arizona • La Jolla, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 31, 2026, 2:31 AM EDT
Withdrawn Not applicable Interventional

Raltegravir Activity In Lymphoid Tissues

NCT00863668
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Efavirenz + Tenofovir DF/Emtricitabine, Raltegravir + Tenofovir DF/Emtricitabine, Colonoscopy with biopsies, Inguinal Lymph Node Excision
Drug · Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Oct 31, 2026, 2:31 AM EDT